Promising pharmacological directions in the world of lysophosphatidic acid signaling

Biomolecules and Therapeutics

Volumn 23, Issue 1, 2015, Pages 1-11

  Stoddard, Nicole C ^a,b   Chun, Jerold ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune disease; Autotaxin; Cancer; Fibrosis; Lysophosphatidic acid receptor; Pharmacology

Indexed keywords

4PBPA; AGENTS AFFECTING LIPID METABOLISM; AGENTS AFFECTING PROTEIN METABOLISM; ALPHA BROMOMETHYLENE PHOSPHONATE LYSOPHOSPHATIDIC ACID; AM 095; AM 966; AUTOTAXIN; AUTOTAXIN INHIBITOR; BMS 986020; BMS 986202; COMPOUND 35; DEBIO 0719; FINGOLIMOD; GINTONIN; GWJ A 23; HLZ 56; KI 16198; KI 16425; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID ANTIBODY; LYSOPHOSPHATIDIC ACID INHIBITOR; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST; ONO 8430506; PF 8380; S 32826; SAR 100842; UNCLASSIFIED DRUG; VPC 12249;

ARTHRITIS; ARTICLE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; FIBROSIS; HYDROCEPHALUS; INJURY; LIPOGENESIS; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

EID: 84919953381     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2014.109     Document Type: Article

References (100)

1. An, S., Bleu, T., Hallmark, O. G. and Goetzl, E. J. (1998) Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273, 7906-7910.
2. Azeem, Z., Jelani, M., Naz, G., Tariq, M., Wasif, N., Kamran-Ul-Hassan Naqvi, S., Ayub, M., Yasinzai, M., Amin-Ud-Din, M., Wali, A., Ali, G., Chishti, M. S. and Ahmad, W. (2008) Novel mutations in G proteincoupled receptor gene (P2RY5) in families with autosomal recessive hypotrichosis (LAH3). Hum. Genet.123, 515-519.
3. Bachner, D., Ahrens, M., Betat, N., Schroder, D. and Gross, G. (1999) Developmental expression analysis of murine autotaxin (ATX). Mech. Dev. 84, 121-125.
4. Bai, C. Q., Yao, Y. W., Liu, C. H., Zhang, H., Xu, X. B., Zeng, J. L., Liang, W. J., Yang, W. and Song, Y. (2014) Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions. J. Thorac. Dis. 6, 483-490.
5. Bandoh, K., Aoki, J., Hosono, H., Kobayashi, S., Kobayashi, T., Murakami- Murofushi, K., Tsujimoto, M., Arai, H. and Inoue, K. (1999) Molecular cloning and characterization of a novel human G-protein- coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 274, 27776-27785.
6. Beck, H. P., Kohn, T., Rubenstein, S., Hedberg, C., Schwandner, R., Hasslinger, K., Dai, K., Li, C., Liang, L., Wesche, H., Frank, B., An, S., Wickramasinghe, D., Jaen, J., Medina, J., Hungate, R. and Shen, W. (2008) Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg. Med. Chem. Lett. 18, 1037- 1041.
7. Benesch, M. G., Tang, X., Maeda, T., Ohhata, A., Zhao, Y. Y., Kok, B. P., Dewald, J., Hitt, M., Curtis, J. M., McMullen, T. P. and Brindley, D. N. (2014) Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J. 28, 2655-2666.
8. Bhave, S. R., Dadey, D. Y., Karvas, R. M., Ferraro, D. J., Kotipatruni, R. P., Jaboin, J. J., Hallahan, A. N., Dewees, T. A., Linkous, A. G., Hallahan, D. E. and Thotala, D. (2013) Autotaxin inhibition with PF- 8380 enhances the radiosensitivity of human and murine glioblastoma cell lines. Front. Oncol. 3, 236.
9. BMS (2011) Bristol-myers squibb to acquire amira pharmaceuticals. Bristol-Myers Squibb, Online. http://news.bms.com/press-release/ partnering-news/bristol-myers-squibb-acquire-amira-pharmaceuticals, Access Date: 2014/09/15
10. BMS (2014) Safety and efficacy of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis. https://clinicaltrials.gov/ ct2/show/NCT01766817, Access Date: 2014/09/15.
11. Bradford, W. Z. (2012) Pirfenidone and anti-fibrotic therapy in selected patients, International Patent: WO/2012/162592 A1. Intermune, Inc., International. http://www.google.im/patents/WO2012162592A1, Access Date: 2014/09/15.
12. Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., Foster, C. A., Zollinger, M. and Lynch, K. R. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453-21457.
13. Calabresi, P. A., Radue, E. W., Goodin, D., Jeffery, D., Rammohan, K. W., Reder, A. T., Vollmer, T., Agius, M. A., Kappos, L., Stites, T., Li, B., Cappiello, L., von Rosenstiel, P. and Lublin, F. D. (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo- controlled, phase 3 trial. Lancet Neurol. 13, 545-556.
14. Castelino, F. V., Seiders, J., Bain, G., Brooks, S. F., King, C. D., Swaney, J. S., Lorrain, D. S., Chun, J., Luster, A. D. and Tager, A. M. (2011) Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum.63, 1405-1415.
15. Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C. W., Mutoh, T., Lin, M. E., Teo, S. T., Park, K. E., Mosley, A. N. and Chun, J. (2010) LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 50, 157-186.
16. Chun, J. and Hartung, H. P. (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 33, 91-101.
17. Chun, J., Hla, T., Lynch, K. R., Spiegel, S. and Moolenaar, W. H. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 62, 579- 587.
18. Contos, J. J., Ishii, I., Fukushima, N., Kingsbury, M. A., Ye, X., Kawamura, S., Brown, J. H. and Chun, J. (2002) Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol. Cell. Biol. 22, 6921-6929.
19. Crack, P. J., Zhang, M., Morganti-Kossmann, M. C., Morris, A. J., Wojciak, J. M., Fleming, J. K., Karve, I., Wright, D., Sashindranath, M., Goldshmit, Y., Conquest, A., Daglas, M., Johnston, L. A., Medcalf, R. L., Sabbadini, R. A. and Pebay, A. (2014) Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes. J. Neuroinflammation 11, 37.
20. Cummings, R., Zhao, Y., Jacoby, D., Spannhake, E. W., Ohba, M., Garcia, J. G., Watkins, T., He, D., Saatian, B. and Natarajan, V. (2004) Protein kinase Cdelta mediates lysophosphatidic acid-induced NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. J. Biol. Chem. 279, 41085-41094.
21. Eichholtz, T., Jalink, K., Fahrenfort, I. and Moolenaar, W. H. (1993) The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 291 (Pt 3), 677-680.
22. Fells, J. I., Lee, S. C., Fujiwara, Y., Norman, D. D., Lim, K. G., Tsukahara, R., Liu, J., Patil, R., Miller, D. D., Kirby, R. J., Nelson, S., Seibel, W., Papoian, R., Parrill, A. L., Baker, D. L., Bittman, R. and Tigyi, G. (2013) Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface. Mol. Pharmacol. 84, 415-424.
23. Fourcade, O., Simon, M. F., Viode, C., Rugani, N., Leballe, F., Ragab, A., Fournie, B., Sarda, L. and Chap, H. (1995) Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 80, 919- 927.
24. Fukushima, N., Ishii, I., Contos, J. J., Weiner, J. A. and Chun, J. (2001) Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 41, 507-534.
25. Geng, H., Lan, R., Singha, P. K., Gilchrist, A., Weinreb, P. H., Violette, S. M., Weinberg, J. M., Saikumar, P. and Venkatachalam, M. A. (2012) Lysophosphatidic acid increases proximal tubule cell secretion of profibrotic cytokines PDGF-B and CTGF through LPA2- and Galphaq-mediated Rho and alphavbeta6 integrin-dependent activation of TGF-beta. Am. J. Pathol. 181, 1236-1249.
26. Gerrard, J. M., Kindom, S. E., Peterson, D. A., Peller, J., Krantz, K. E. and White, J. G. (1979) Lysophosphatidic acids. Influence on platelet aggregation and intracellular calcium flux. Am. J. Pathol. 96, 423-438.
27. Gierse, J., Thorarensen, A., Beltey, K., Bradshaw-Pierce, E., Cortes- Burgos, L., Hall, T., Johnston, A., Murphy, M., Nemirovskiy, O., Ogawa, S., Pegg, L., Pelc, M., Prinsen, M., Schnute, M., Wendling, J., Wene, S., Weinberg, R., Wittwer, A., Zweifel, B. and Masferrer, J. (2010) A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J. Pharmacol. Exp. Ther. 334, 310-317.
28. Goldshmit, Y., Matteo, R., Sztal, T., Ellett, F., Frisca, F., Moreno, K., Crombie, D., Lieschke, G. J., Currie, P. D., Sabbadini, R. A. and Pebay, A. (2012) Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes. Am. J. Pathol. 181, 978-992.
29. Gotoh, M., Fujiwara, Y., Yue, J., Liu, J., Lee, S., Fells, J., Uchiyama, A., Murakami-Murofushi, K., Kennel, S., Wall, J., Patil, R., Gupte, R., Balazs, L., Miller, D. D. and Tigyi, G. J. (2012) Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem. Soc. Trans. 40, 31-36.
30. Gupte, R., Patil, R., Liu, J., Wang, Y., Lee, S. C., Fujiwara, Y., Fells, J., Bolen, A. L., Emmons-Thompson, K., Yates, C. R., Siddam, A., Panupinthu, N., Pham, T. C., Baker, D. L., Parrill, A. L., Mills, G. B., Tigyi, G. and Miller, D. D. (2011) Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. ChemMedChem 6, 922-935.
31. Hama, K., Aoki, J., Fukaya, M., Kishi, Y., Sakai, T., Suzuki, R., Ohta, H., Yamori, T., Watanabe, M., Chun, J. and Arai, H. (2004) Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J. Biol. Chem.279, 17634-17639.
32. Hayashi, M., Okabe, K., Kato, K., Okumura, M., Fukui, R., Fukushima, N. and Tsujiuchi, T. (2012) Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells. Cancer Lett. 316, 91-96.
33. Hecht, J. H., Weiner, J. A., Post, S. R. and Chun, J. (1996) Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 135, 1071-1083.
34. Hoelzinger, D. B., Nakada, M., Demuth, T., Rosensteel, T., Reavie, L. B. and Berens, M. E. (2008) Autotaxin: a secreted autocrine/ paracrine factor that promotes glioma invasion. J. Neurooncol. 86, 297-309.
35. Hwang, S. H., Lee, B. H., Kim, H. J., Cho, H. J., Shin, H. C., Im, K. S., Choi, S. H., Shin, T. J., Lee, S. M., Nam, S. W., Kim, H. C., Rhim, H. and Nah, S. Y. (2013) Suppression of metastasis of intravenouslyinoculated B16/F10 melanoma cells by the novel ginseng-derived ingredient, gintonin: involvement of autotaxin inhibition. Int. J. Oncol.42, 317-326.
36. Im, D. S. (2010) Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol. Sin. 31, 1213-1222.
37. Ishii, I., Fukushima, N., Ye, X. and Chun, J. (2004) Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73, 321-354.
38. Iyer, P., Lalane, R., 3rd, Morris, C., Challa, P., Vann, R. and Rao, P. V. (2012) Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure. PloS ONE 7, e42627.
39. Jeong, K. J., Park, S. Y., Cho, K. H., Sohn, J. S., Lee, J., Kim, Y. K., Kang, J., Park, C. G., Han, J. W. and Lee, H. Y. (2012) The Rho/ ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 31, 4279-4289.
40. Jimenez, C., Portela, R. A., Mellado, M., Rodriguez-Frade, J. M., Collard, J., Serrano, A., Martinez, A. C., Avila, J. and Carrera, A. C. (2000) Role of the PI3K regulatory subunit in the control of actin organization and cell migration. J. Cell Biol. 151, 249-262.
41. Jongsma, M., Matas-Rico, E., Rzadkowski, A., Jalink, K. and Moolenaar, W. H. (2011) LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor. PloS ONE 6, e29260.
42. Kanda, H., Newton, R., Klein, R., Morita, Y., Gunn, M. D. and Rosen, S. D. (2008) Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat. Immunol. 9, 415-423.
43. Kang, Y. C., Kim, K. M., Lee, K. S., Namkoong, S., Lee, S. J., Han, J. A., Jeoung, D., Ha, K. S., Kwon, Y. G. and Kim, Y. M. (2004) Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ. 11, 1287-1298.
44. Kawaguchi, M., Okabe, T., Okudaira, S., Nishimasu, H., Ishitani, R., Kojima, H., Nureki, O., Aoki, J. and Nagano, T. (2013) Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe. ACS Chem. Biol. 8, 1713-1721.
45. Kim, J. H. and Adelstein, R. S. (2011) LPA(1) -induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J. Cell. Physiol. 226, 2881-2893.
46. Komachi, M., Sato, K., Tobo, M., Mogi, C., Yamada, T., Ohta, H., Tomura, H., Kimura, T., Im, D. S., Yanagida, K., Ishii, S., Takeyoshi, I. and Okajima, F. (2012) Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo. Cancer Sci. 103, 1099-1104.
47. Kotarsky, K., Boketoft, A., Bristulf, J., Nilsson, N. E., Norberg, A., Hansson, S., Owman, C., Sillard, R., Leeb-Lundberg, L. M. and Olde, B. (2006) Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther. 318, 619-628.
48. Kranenburg, O. and Moolenaar, W. H. (2001) Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene 20, 1540-1546.
49. Lafyatis, R. (2014) Transforming growth factor beta-at the centre of systemic sclerosis. Nat. Rev. Rheumatol. 10, 706-719.
50. Lee, C. W., Rivera, R., Gardell, S., Dubin, A. E. and Chun, J. (2006) GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 281, 23589-23597.
51. Lee, H., Goetzl, E. J. and An, S. (2000) Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. American journal of physiology. Am. J. Physiol. Cell Physiol. 278, C612-618.
52. Lee, Z., Cheng, C. T., Zhang, H., Subler, M. A., Wu, J., Mukherjee, A., Windle, J. J., Chen, C. K. and Fang, X. (2008) Role of LPA4/ p2y9/GPR23 in negative regulation of cell motility. Mol. Biol. Cell 19, 5435-5445.
53. Liao, Y., Mu, G., Zhang, L., Zhou, W., Zhang, J. and Yu, H. (2013) Lysophosphatidic acid stimulates activation of focal adhesion kinase and paxillin and promotes cell motility, via LPA1-3, in human pancreatic cancer. Dig. Dis. Sci. 58, 3524-3533.
54. Lin, D. A. and Boyce, J. A. (2006) Lysophospholipids as mediators of immunity. Ad. Immunol. 89, 141-167.
55. Lu, W. Y., Xiong, Z. G., Lei, S., Orser, B. A., Dudek, E., Browning, M. D. and MacDonald, J. F. (1999) G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat. Neurosci. 2, 331-338.
56. Lundequist, A. and Boyce, J. A. (2011) LPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1beta release. PloS ONE 6, e18192.
57. Marshall, J. C., Collins, J. W., Nakayama, J., Horak, C. E., Liewehr, D. J., Steinberg, S. M., Albaugh, M., Vidal-Vanaclocha, F., Palmieri, D., Barbier, M., Murone, M. and Steeg, P. S. (2012) Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J. Natl. Cancer Inst. 104, 1306-1319.
58. Mills, G. B., Eder, A., Fang, X., Hasegawa, Y., Mao, M., Lu, Y., Tanyi, J., Tabassam, F. H., Wiener, J., Lapushin, R., Yu, S., Parrott, J. A., Compton, T., Tribley, W., Fishman, D., Stack, M. S., Gaudette, D., Jaffe, R., Furui, T., Aoki, J. and Erickson, J. R. (2002) Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat. Res. 107, 259-283.
59. Mirendil, H., Lin, M.-E. and Chun, J. (2013) Lysophospholipid receptors: signaling and biochemistry. In lysophospholipid receptors: signaling and biochemistry (J. Chun, T. Hla, S. Spiegel and W. H. Moolenaar, Eds.) John Wiley & Sons, Inc., Hoboken, NJ.
60. Moolenaar, W. H. and van Corven, E. J. (1990) Growth factor-like action of lysophosphatidic acid: mitogenic signalling mediated by G proteins. Ciba Found. Symp. 150, 99-106.
61. Morimoto, T. (2012) Tetrahydrocarboline derivative, International Patent: WO/2012/ 005227 A1. Ono Pharmaceutical Co., Ltd., International. http://www.google.com/patents/WO2012005227A1, Access Date: 2014/ 09/15.
62. NCI (2014) A pilot study of a protein profile test in ovarian cancer patients in remission to see if protein changes can predict relapse. https://clinicaltrials.gov/ct2/show/NCT00001938, Access Date: 2014/09/15.
63. Nikitopoulou, I., Kaffe, E., Sevastou, I., Sirioti, I., Samiotaki, M., Madan, D., Prestwich, G. D. and Aidinis, V. (2013) A metabolicallystabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis. PloS ONE 8, e70941.
64. Noguchi, K., Ishii, S. and Shimizu, T. (2003) Identification of p2y9/ GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 278, 25600-25606.
65. Nogueira, E. S. and Vales, R. L. (2013) Methods for treating spinal cord injury with lpa receptor antagonists, International Patent: WO/2013/070879 A1. Bristol-Myers Squibb, International. http://www.google.com/patents/WO2013070879A, Access Date: 2014/09/15.
66. Norman, D. D., Ibezim, A., Scott, W. E., White, S., Parrill, A. L. and Baker, D. L. (2013) Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds. Bioorg. Med. Chem. 21, 5548-5560.
67. Oikonomou, N., Mouratis, M. A., Tzouvelekis, A., Kaffe, E., Valavanis, C., Vilaras, G., Karameris, A., Prestwich, G. D., Bouros, D. and Aidinis, V. (2012) Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 47, 566-574.
68. Okusa, M. D., Ye, H., Huang, L., Sigismund, L., Macdonald, T. and Lynch, K. R. (2003) Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. American journal of physiology. Am. J. Physol. Renal Physiol. 285, F565-574.
69. Orosa, B., Garcia, S., Martinez, P., Gonzalez, A., Gomez-Reino, J. J. and Conde, C. (2014) Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis. Am. Rheum. Dis. 73, 298-305.
70. Park, G. Y., Lee, Y. G., Berdyshev, E., Nyenhuis, S., Du, J., Fu, P., Gorshkova, I. A., Li, Y., Chung, S., Karpurapu, M., Deng, J., Ranjan, R., Xiao, L., Jaffe, H. A., Corbridge, S. J., Kelly, E. A., Jarjour, N. N., Chun, J., Prestwich, G. D., Kaffe, E., Ninou, I., Aidinis, V., Morris, A. J., Smyth, S. S., Ackerman, S. J., Natarajan, V. and Christman, J. W. (2013) Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. Am. J. Respir. Crit. Care Med. 188, 928-940.
71. Pasternack, S. M., von Kugelgen, I., Al Aboud, K., Lee, Y. A., Ruschendorf, F., Voss, K., Hillmer, A. M., Molderings, G. J., Franz, T., Ramirez, A., Nurnberg, P., Nothen, M. M. and Betz, R. C. (2008) G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat. Genet. 40, 329-334.
72. Petukhova, L., Sousa, E. C., Jr., Martinez-Mir, A., Vitebsky, A., Dos Santos, L. G., Shapiro, L., Haynes, C., Gordon, D., Shimomura, Y. and Christiano, A. M. (2008) Genome-wide linkage analysis of an autosomal recessive hypotrichosis identifies a novel P2RY5 mutation. Genomics 92, 273-278.
73. Ruisanchez, E., Dancs, P., Kerek, M., Nemeth, T., Farago, B., Balogh, A., Patil, R., Jennings, B. L., Liliom, K., Malik, K. U., Smrcka, A. V., Tigyi, G. and Benyo, Z. (2014) Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. FASEB J. 28, 880-890.
74. Sando, J. J. and Chertihin, O. I. (1996) Activation of protein kinase C by lysophosphatidic acid: dependence on composition of phospholipid vesicles. Biochem. J. 317 (Pt 2), 583-588.
75. Sano, T., Baker, D., Virag, T., Wada, A., Yatomi, Y., Kobayashi, T., Igarashi, Y. and Tigyi, G. (2002) Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J. Biol. Chem. 277, 21197-21206.
76. Sanofi (2014) Proof of Biological Activity of SAR100842 in Systemic Sclerosis. https://clinicaltrials.gov/ct2/show/NCT01651143, Access Date: 2014/09/15.
77. Savaskan, N. E., Rocha, L., Kotter, M. R., Baer, A., Lubec, G., van Meeteren, L. A., Kishi, Y., Aoki, J., Moolenaar, W. H., Nitsch, R. and Brauer, A. U. (2007) Autotaxin (NPP-2) in the brain: cell typespecific expression and regulation during development and after neurotrauma. Cell. Mol. Life Sci. 64, 230-243.
78. Schleicher, S. M., Thotala, D. K., Linkous, A. G., Hu, R., Leahy, K. M., Yazlovitskaya, E. M. and Hallahan, D. E. (2011) Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PloS ONE 6, e22182.
79. Sedlakova, I., Vavrova, J., Tosner, J. and Hanousek, L. (2011) Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer. Tumor Biol. 32, 311-316.
80. Seewald, S., Schmitz, U., Seul, C., Ko, Y., Sachinidis, A. and Vetter, H. (1999) Lysophosphatidic acid stimulates protein kinase C isoforms alpha, beta, epsilon, and zeta in a pertussis toxin sensitive pathway in vascular smooth muscle cells. Am. J. Hypertens. 12, 532-537.
81. Sonoda, H., Aoki, J., Hiramatsu, T., Ishida, M., Bandoh, K., Nagai, Y., Taguchi, R., Inoue, K. and Arai, H. (2002) A novel phosphatidic acid- selective phospholipase A1 that produces lysophosphatidic acid. J. Biol. Chem. 277, 34254-34263.
82. Sotiropoulos, A., Gineitis, D., Copeland, J. and Treisman, R. (1999) Signal-regulated activation of serum response factor is mediated by changes in actin dynamics. Cell 98, 159-169.
83. St-Coeur, P. D., Ferguson, D., Morin, P., Jr. and Touaibia, M. (2013) PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability. Arch. Pharm. 346, 91-97.
84. Su, S. C., Hu, X., Kenney, P. A., Merrill, M. M., Babaian, K. N., Zhang, X. Y., Maity, T., Yang, S. F., Lin, X. and Wood, C. G. (2013) Autotaxin- lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma. Clin. Cancer Res. 19, 6461-6472.
85. Swaney, J. S., Chapman, C., Correa, L. D., Stebbins, K. J., Broadhead, A. R., Bain, G., Santini, A. M., Darlington, J., King, C. D., Baccei, C. S., Lee, C., Parr, T. A., Roppe, J. R., Seiders, T. J., Ziff, J., Prasit, P., Hutchinson, J. H., Evans, J. F. and Lorrain, D. S. (2011) Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J. Pharmacol. Exp. Ther. 336, 693-700.
86. Swaney, J. S., Chapman, C., Correa, L. D., Stebbins, K. J., Bundey, R. A., Prodanovich, P. C., Fagan, P., Baccei, C. S., Santini, A. M., Hutchinson, J. H., Seiders, T. J., Parr, T. A., Prasit, P., Evans, J. F. and Lorrain, D. S. (2010) A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br. J. Pharmacol. 160, 1699-1713.
87. Tanaka, M., Okudaira, S., Kishi, Y., Ohkawa, R., Iseki, S., Ota, M., Noji, S., Yatomi, Y., Aoki, J. and Arai, H. (2006) Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281, 25822-25830.
88. Tokumura, A., Fukuzawa, K., Akamatsu, Y., Yamada, S., Suzuki, T. and Tsukatani, H. (1978) Identification of vasopressor phospholipid in crude soybean lecithin. Lipids 13, 468-472.
89. Tokumura, A., Majima, E., Kariya, Y., Tominaga, K., Kogure, K., Yasuda, K. and Fukuzawa, K. (2002) Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277, 39436-39442.
90. Ueda, H., Matsunaga, H., Olaposi, O. I. and Nagai, J. (2013) Lysophosphatidic acid: chemical signature of neuropathic pain. Biochim. Biophys. Acta 1831, 61-73.
91. Umezu-Goto, M., Kishi, Y., Taira, A., Hama, K., Dohmae, N., Takio, K., Yamori, T., Mills, G. B., Inoue, K., Aoki, J. and Arai, H. (2002) Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158, 227-233.
92. Valet, P., Pages, C., Jeanneton, O., Daviaud, D., Barbe, P., Record, M., Saulnier-Blache, J. S. and Lafontan, M. (1998) Alpha2-adrenergic receptor-mediated release of lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth. J. Clin. Invest. 101, 1431-1438.
93. van Meeteren, L. A., Ruurs, P., Stortelers, C., Bouwman, P., van Rooijen, M. A., Pradere, J. P., Pettit, T. R., Wakelam, M. J., Saulnier- Blache, J. S., Mummery, C. L., Moolenaar, W. H. and Jonkers, J. (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 26, 5015-5022.
94. Xu, X. and Prestwich, G. D. (2010) Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 116, 1739- 1750.
95. Yanagida, K., Masago, K., Nakanishi, H., Kihara, Y., Hamano, F., Tajima, Y., Taguchi, R., Shimizu, T. and Ishii, S. (2009) Identification and Characterization of a Novel Lysophosphatidic Acid Receptor, p2y5/LPA6. J. Biol. Chem. 284, 17731-17741.
96. Ye, X., Hama, K., Contos, J. J., Anliker, B., Inoue, A., Skinner, M. K., Suzuki, H., Amano, T., Kennedy, G., Arai, H., Aoki, J. and Chun, J. (2005) LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435, 104-108.
97. Ye, X., Ishii, I., Kingsbury, M. A. and Chun, J. (2002) Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim. Biophys. Acta 1585, 108-113.
98. Yung, Y. C., Mutoh, T., Lin, M. E., Noguchi, K., Rivera, R. R., Choi, J. W., Kingsbury, M. A. and Chun, J. (2011) Lysophosphatidic acid signaling may initiate fetal hydrocephalus. Sci. Transl. Med. 3, 99ra87.
99. Yung, Y. C., Stoddard, N. C. and Chun, J. (2014) LPA receptor signaling: pharmacology, physiology, and pathophysiology. J. Lipid Res. 55, 1192-1214.
100. Zhang, H., Xu, X., Gajewiak, J., Tsukahara, R., Fujiwara, Y., Liu, J., Fells, J. I., Perygin, D., Parrill, A. L., Tigyi, G. and Prestwich, G. D. (2009) Dual activity lysophosphatidic acid receptor pan-antagonist/ autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 69, 5441-5449.